Innoviva (INVA) Stock Price
Innoviva Price
Revenue has compounded at 17.6% per year over the past 19 years to 425.13 M USD. Earnings per share have grown at 22.9% per year over the last 9 years. Innoviva's net margin stands at 63.8%, down from 67.8% several years earlier. Innoviva currently offers a dividend yield of about 3.56%. Analysts set a median price target of 38.00 USD, implying 80.4% above the current price. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus.
Innoviva stock price
Innoviva business model & stock analysis
Frequently asked questions about Innoviva
Innoviva Inc's business model focuses on the development and commercialization of new therapies for respiratory diseases. The company collaborates with pharmaceutical partners to license and acquire royalty interests in their products. By monetizing these interests, Innoviva generates a steady stream of revenue, allowing them to invest in research and development activities. This strategic approach ensures a diversified portfolio of respiratory medicines and enables Innoviva to support the innovation and advancement of healthcare solutions.
Innoviva Inc is primarily active in the healthcare and pharmaceutical industries.
The main competitors of Innoviva Inc in the market include pharmaceutical and biotechnology companies such as GlaxoSmithKline, Novartis, AstraZeneca, and Merck & Co.
Innoviva Inc, formerly known as Theravance Inc, is a biopharmaceutical company specializing in the development and commercialization of innovative therapies. Founded in 1996, Innoviva has a rich history of partnering with leading pharmaceutical companies to bring breakthrough treatments to market. With a focus on respiratory diseases, Innoviva is committed to improving the lives of patients suffering from conditions such as asthma and chronic obstructive pulmonary disease (COPD). The company has an impressive portfolio of products and continues to invest in research and development to address unmet medical needs. Innoviva's dedication to innovation and strategic collaborations has positioned it as a leader in the biopharmaceutical industry.
Innoviva Inc, a leading stock company, has achieved several significant milestones throughout its history. The company has successfully forged strategic partnerships with renowned pharmaceutical companies, facilitating the development and commercialization of innovative respiratory therapies. Innoviva Inc has also consistently delivered impressive financial results, showcasing its strong market position and value creation for shareholders. Furthermore, the company has been focused on enhancing its pipeline of respiratory products and expanding its global footprint. With its continued commitment to innovation and strategic growth, Innoviva Inc remains a prominent player in the stock market, presenting lucrative opportunities for investors.
Innoviva Inc is primarily present in the United States.
Innoviva Inc is committed to delivering value to its shareholders and stakeholders through innovation and collaboration. The company's corporate philosophy is focused on providing innovative solutions in the field of respiratory diseases. Innoviva Inc prides itself on fostering a culture of excellence, integrity, and patient-centricity. With a dedicated team and strategic partnerships, the company strives to enhance the quality of life for individuals suffering from respiratory conditions. Innoviva Inc's commitment to research, development, and commercialization of novel therapies underscores its mission to make a meaningful difference in the lives of patients worldwide.
Analysts currently set an average price target of 38.00 USD for the Innoviva stock (median: 38.00 USD), implying +80.4 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the Innoviva stock: 9 recommend buying, 1 holding and 1 selling. For 2026, analysts expect Innoviva to generate revenue of 451.29 M USD and earnings per share of 2.12 USD.
Converted at the current exchange rate, the Innoviva share trades at 18.81 EUR (21.06 USD).
The Innoviva share (INVA) is listed on 5 stock exchanges, including: NASDAQ (INVA), SIX (Zürich) (HVE.SW), Frankfurt (HVE.F), München (HVE.MU), Düsseldorf (HVE.DU).
Innoviva Inc. is a publicly traded company based in California, USA, that focuses on the development and marketing of medications in collaboration with its partners. The company has two main business areas: partnerships with the pharmaceutical industry and the sale of licenses. In the first area, Innoviva specializes in the development of medications for respiratory diseases and has partnerships with leading pharmaceutical companies such as GlaxoSmithKline and Theravance Biopharma. In the second area, Innoviva offers its extensive patent portfolio to partner companies for use and actively seeks potential partners who can benefit from certain patents. Overall, Innoviva has a strong position in the respiratory disease market and is known for its innovative and effective medications.
The expected revenue of Innoviva is 451.29 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Innoviva is 180.94 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Innoviva is currently 9.92. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Innoviva stock.
The price-to-sales ratio (P/S) of Innoviva is currently 3.98. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Innoviva stock.
The Eulerpool Quality Score for Innoviva is 5/10.
The ISIN of Innoviva is US45781M1018. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Innoviva is A2AC9U. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Innoviva is INVA. The ticker symbol is used to trade Innoviva shares on the stock exchange.
Innoviva stock
Innoviva Peer Group
Innoviva Ticker
Innoviva FIGI
All fundamentals and in-depth analysis of Innoviva
Our stock analysis for Innoviva stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innoviva. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.